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Abstract 38 
In addition to cholesterol lowering capabilities, statins possess antiinflammatory and 39 
immunomodulatory effects. We sought to quantify the real-world impact of different 40 
statin exposure patterns on clinical outcomes in Staphylococcus aureus bacteremia. We 41 
conducted a retrospective cohort study among hospitalized patients with positive S. 42 
aureus blood cultures receiving appropriate antibiotics within 48 hours of culture 43 
collection (Veterans Affairs hospitals, 2002-2013). Three statin exposure groups were 44 
compared to non-users: pretreated statin users initiating therapy in the 30 days prior to 45 
culture and either (1) continuing statin therapy after culture, or (2) not continuing after 46 
culture, and (3) de novo users initiating at culture. Non-users included patients without 47 
statins in the year prior to culture through discharge. Propensity score matched Cox 48 
proportional hazards regression models were developed. We were able to balance 49 
significantly different baseline characteristics using propensity score matching for 50 
pretreated without continuation (n=331), pretreated with continuation (n=141), and de 51 
novo (n=177) statin users as compared to non-users. We observed a significantly lower 52 
30-day mortality rate (hazard ratio [HR] 0.46, 95% confidence interval [CI] 0.25-0.84; 53 
number needed to treat [NNT] 10) among pretreated and continued statin users, while 54 
protective effects were not observed in de novo (HR 1.04, 95% CI 0.60-1.82; NNT 55 
undefined) or pretreated but not continued (HR 0.92, 95% CI 0.64-1.32; NNT 47) users. 56 
In our national cohort study among patients with S. aureus bacteremia, continuation of 57 
statin therapy among incident statin users was associated with significant beneficial 58 
effects on mortality, including a 54% lower 30-day mortality rate.   59 
 60 
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Introduction 61 
Statins, selective and competitive inhibitors of 3-hydroxy 3-methylglutaryl coenzyme A 62 
(HMG-CoA) reductase, are widely used for primary and secondary prevention of 63 
cardiovascular diseases (1). The anti-inflammatory, immunomodulatory, and endothelial 64 
barrier protection potential of statins have received considerable research attention (1). 65 
It has been postulated that the pleiotropic effect of statins may reflect reduced pathogen 66 
invasion of host cells (2), decreased levels of proinflammatory cytokines (e.g. tumor 67 
necrosis factor-α [TNF-α]), interleukin-6 [ΙL-6]), and acute phase proteins such as C-68 
reactive protein) (3, 4), or diminished activation of inflammatory cells (e.g. 69 
macrophages, T-cells) (5, 6). In fact, a randomized double-blind placebo controlled 70 
clinical trial among patients with bacterial infections found significant reductions in TNF-71 
α and ΙL-6 levels in the statin group compared to the placebo group (7) and another trial 72 
observed sinficantly lower IL-6 and improved survival among prior statin users 73 
continuing statin therapy (8).  74 
 75 
Staphylococcus aureus is one of the most prevalent pathogens of bacteremia (9). S. 76 
aureus bacteremia is associated with a significant burden of disease and a high case 77 
fataility, ranging from 20-30% (10). Laboratory studies have found that statins inhibit S. 78 
aureus invasion of human endothelial cells (2, 11) and enhance clearance of S. aureus 79 
by phagocytes through the induction of DNA-based extracellular traps (12). Whether 80 
these impressive laboratory observations with statins consistenly result in significant 81 
real-world clinical benefits in complex patients with invasive S. aureus infections 82 
remains unclear. Even less clear is the relationship between statin therapy timing and 83 
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duration and subsequent effects on mortality, including the impact of statin initiation at 84 
admission/culture, as adjunctive therapy to antibiotics. Though two large meta-analyses 85 
have demonstrated protective effects with statins, exposure periods prior to 86 
hospitalization (pretreated) and during hospitalization (continuation, de novo) vary 87 
widely (13, 14). Therefore, the purpose of this study was to compare clinical outcomes 88 
in patients with S. aureus bacteremia with various statin exposure patterns to those not 89 
exposed to statins among a large, national cohort.  90 
 91 
Methods 92 
Data Source 93 
The Veterans Health Administration is a nationwide healthcare system for Veterans in 94 
the United States (US) which has utilized an electronic medical record since 1999 (15). 95 
National VA databases provide comprehensive information on patient care, including 96 
International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) 97 
diagnostic and procedure codes, laboratory and microbiology results, vital signs and 98 
vital status, and pharmacy data including barcode medication administration records for 99 
inpatients, inpatient and outpatient prescription and fill records, and medications 100 
prescribed by non-VA providers or purchased by patients at non-VA pharmacies. This 101 
study was approved by the Institutional Review Board and Research and Development 102 
Committee at the Providence Veterans Affairs Medical Center. The methods described 103 
hereafter were pre-specified in our research plan. 104 
 105 
Study Population 106 
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We conducted a retrospective cohort study quantifying the effect of statin use on clinical 107 
outcomes among patients with S. aureus bacteremia. We identified adult patients (age ≥ 108 
18 years) admitted to VA hospitals whose blood cultures were positive for S. aureus 109 
between January 1, 2002 and December 1, 2013. We then assessed antibiotic therapy 110 
for each patient during the hospital admission. We included patients who received 111 
intravenous β-lactam therapy (ampicillin-sulbactam, nafcillin, oxacillin, piperacillin-112 
tazobactam, cefazolin, cefotetan, cefoxitin, ceftazidime, ceftriaxone, ceftaroline, 113 
ertapenem, doripenem, imipenem-cilastatin, or meropenem) or vancomycin for 114 
methicillin-susceptible S. aureus [MSSA] and vancomycin or ceftaroline for methicillin-115 
resistant S. aureus [MRSA] within 48 hours of culture collection. Due to the existing 116 
labeling guidance (drug interactions) on temporality suspending statins in patients 117 
receiving daptomycin, we did not include patients with initial daptomycin therapy. We 118 
excluded patients who died or were discharged on the day of culture or the day after 119 
culture. We only evaluated the first admission within the study period after accounting 120 
for all inclusion and exclusion criteria. 121 
 122 
Statin Use  123 
All statin users were incident users not having used statins in the one year prior to 124 
culture. The study was designed with this restriction criterion to avoid healthy user bias. 125 
We defined incident pretreated statin users as those initiating a statin (i.e. atorvastatin, 126 
fluvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin) in the 30 days prior to 127 
culture collection. Among pretreated statin users, we included those continuing therapy 128 
for at least three days after culture (pretreated with continuation) and those not 129 
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continuing therapy after culture (pretreated without continuation). De novo users 130 
initiated statins on the day of culture or the day after culture. Non-users included 131 
patients without any pharmacy records for statins in the year prior to culture collection 132 
through discharge. 133 
 134 
Outcomes 135 
Our primary outcome was time to 30-day mortality, defined as mortality within 30 days 136 
of the index date, i.e. the culture collection date. The secondary outcomes of interest 137 
were time to 14-day mortality (mortality within 14 days of the index date), inpatient 138 
mortality (mortality during the hospitalization), hospital discharge, intensive care unit 139 
(ICU) discharge, 30-day readmission, and 30-day S. aureus re-infection. We calculated 140 
time for each endpoint from the index date to the event date. ICU discharge was 141 
examined among patients whose cultures were taken while in the ICU. For ICU and 142 
hospital discharge, if patients died during the hospital admission, we censored them on 143 
their date of death. For readmission and re-infection, we computed time from the 144 
hospital discharge date to the event date. Patients who died during the admission were 145 
not included in the evaluation of post-discharge outcomes. We censored patients on 146 
their date of death if they died within 30 days after discharge.  147 
 148 
Statistical Analysis 149 
We assessed baseline differences between statin exposure group and non-users using 150 
a chi-square or Fisher’s exact test for categorical variables and a t-test or non-151 
parametric Wilcoxon Rank Sum test for continuous variables. To generate propensity 152 
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scores (the predicted probability of statin use), we developed an unconditional logistic 153 
regression model using a manual backward elimination approach (16, 17). In the final 154 
propensity score models, we checked for multicollinearity and goodness of fit, and ran 155 
propensity score diagnostics (18). We performed nearest neighbor propensity score 156 
matching within 0.005 caliper (18) and reviewed subsequent covariate balance between 157 
the matched groups (16, 17). 158 
 159 
To quantify the effect of statin therapy on clinical outcomes, we used Cox proportional 160 
hazards regression models. Cox proportional hazards regression assumptions were 161 
assessed, including proportionality (19). These analyses were conducted separately for 162 
each statin exposure group, in which separate propensity score models were built for 163 
pretreated users with continuation, pretreated users without continuation, and de novo 164 
users. Subsequent outcomes, compared to non-users, were assessed separately for 165 
each of these statin exposure groups. A hazard ratio (HR) above 1 indicated an 166 
increased probability of the outcome occurring sooner in the statin exposure group 167 
compared to non-users. Number needed to treat was calculated from risk differences 168 
among matched pairs. In sensitivity analyses, Cox models were adjusted for propensity 169 
score quintiles, with quintile I serving as the reference, and weighted by the inverse 170 
probability of treatment (20). All analyses were performed using SAS (SAS Institute Inc., 171 
Cary, NC, Version 9.2). 172 
 173 
Results 174 
We identified 17,138 patients with S. aureus bacteremia who met our inclusion and 175 
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exclusion criteria (Figure 1). Of them, 16,448 were non-users of statins, 344 were 176 
pretreated without continuation at culture, 159 were pretreated with continuation, and 177 
187 were de novo users. Mean statin duration prior to culture was 7 days both among 178 
those who continued (standard deviation [sd] 6.9, median 5, interquartile range [IQR] 3-179 
10) and those who did not continue (sd 7.7, median 3, IQR 1-11) statin therapy. Statin-180 
exposed patients were significantly older (mean 69.7 to 71.7 years; Table 1) and more 181 
likely to have been in intensive care at the time of culture collection (22.7% to 29.6%) 182 
than non-users (67 years, 19.8% intensive care at culture, p<0.05). Half of non-users 183 
had MSSA and half had MRSA. A similar distribution was observed among the statin 184 
exposure groups, except de novo users were more likely to have MSSA (58.3% versus 185 
50.2%, p<0.05). Sepsis was significantly less common among the pretreated exposure 186 
groups compared to non-users (pretreated without continuation 78.2% versus 83.2%, 187 
p<0.05; pretreated with continuation 72.3% versus 83.2%, p<0.05). 188 
 189 
Comorbidity scores during the hospital admission were similar between the exposed 190 
groups and non-users (Table 2), however there was a lower overall comorbidity burden 191 
in the year prior to the current admission among pretreated users with continuation 192 
(mean Charlson 2.5, sd 2.9) and de novo users (mean Charlson 2.7, sd 3.1) compared 193 
to non-users (mean Charlson 3.2, sd 3.1, p<0.05 for both comparisons). Despite similar 194 
overall comorbidity burden between statin users and non-users, the burden of 195 
cardiovascular diseases was significantly higher among the statin exposure groups, 196 
both during the current admission and in the previous year, as was utilization of 197 
medications for hypertension and diabetes. The overall 30-day mortality rate was 20.2% 198 
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in our study population. The median time to 30-day mortality was similar between non-199 
users (11 days, IQR 5-18, 20.3%) and pretreated statin users without continuation (12 200 
days, IQR 6-18, 19.0%) and de novo users (12 days, IQR 9-17, 16.6%), yet it was 201 
significantly lower among pretreated statin users with continuation of therapy (18 days, 202 
IQR 9-23, 13.8%, p<0.05). 203 
 204 
Baseline characteristics were balanced between statin users and non-users within 205 
propensity score matched pairs (pretreated without continuation, n=331; pretreated with 206 
continuation, n=141; de novo, n=177). Characteristics included in the propensity score 207 
models, including initial antibiotic treatment, treating specialty, MSSA/MRSA, sepsis, 208 
statin indication, and other characteristics independently associated with the exposure 209 
groups or the outcomes, can be found in Supplemental Table 1. Each model 210 
demonstrated goodness of fit, with high C-statistics of 0.86-0.92, indicating excellent 211 
discrimination between the groups (21), and complete overlap in propensity score 212 
distributions between statin exposure groups and non-users (pretreated without 213 
continuation, mean 0.094, sd 0.101, median 0.054, IQR 0.022-0.132; pretreated with 214 
continuation, mean 0.098, sd 0.110, median 0.052, IQR 0.020-0.137; de novo, mean 215 
0.076, sd 0.095, median 0.037, IQR 0.016-0.099). 216 
 217 
Time to event analyses comparing statin users to non-users (reference group) are 218 
presented in Table 3. No significant differences were observed between non-users and 219 
two of the statin exposure groups (pretreated without continuation, de novo) for any of 220 
the outcomes assessed. The rate of 30-day mortality was significantly lower in 221 
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pretreated statin users with continuation compared to propensity matched non-users 222 
(HR 0.46, 95% CI 0.25-0.84) but not among pretreated users who did not continue 223 
statin therapy after culture (HR 0.92, 95% CI 0.64-1.32) or de novo users (HR 1.04, 224 
95% CI 0.60-1.82). Among pretreated statin users continuing statin therapy after 225 
culture, 14-day mortality was also significantly lower than that of non-users (HR 0.35, 226 
95% CI 0.15-0.83), however, significant differences were not observed for the other 227 
outcomes assessed, including inpatient mortality.  228 
 229 
Similar results were observed in sensitivity analyses utilizing propensity score quintile 230 
adjustment (Supplemental Tables 2-4). Sensitivity analyses with inverse probability of 231 
treatment weighting (IPTW) also demonstrated significantly lower mortality rates among 232 
pretreated statin users with continuation (14-day mortality HR 0.15, 95% CI 0.07-0.32); 233 
30-day mortality HR 0.17, 95% CI 0.10-0.30; inpatient mortality HR 1.39, 95% CI 1.19-234 
1.62; Supplemental Tables 2-4). Alternatively, in IPTW analyses, statin users without 235 
continuation had significantly higher mortality compared with non-users, including 14-236 
day mortality (HR 3.81, 95% CI 3.26-4.44), 30-day mortality (HR 2.84, 95% CI 2.46-237 
3.28), and inpatient mortality (3.76, 95% CI 3.23-4.36). In de novo statin users, the 30-238 
day readmission rate was significantly higher than non-users (HR 1.75, 95% CI 1.11-239 
2.75), as was 30-day S. aureus reinfection (HR 12.33, 95% CI 1.21-125.59). 240 
 241 
The 30-day mortality risk difference in pretreated statin users with continuation versus 242 
non-users, was 99 per 1,000 patients (95% CI 10-189 per 1,000) and the number 243 
needed to treat (NNT) was 10. For 14-day mortality, the risk difference was 78 per 244 
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1,000 patients (95% CI 8-148 per 1,000) and the NNT was 13. The 14-day and 30-day 245 
survival probability curves for pretreated statin users with continuation versus non-users 246 
can be found in Figure 2. 247 
 248 
Discussion 249 
Recent statin initiation with continuation of statin therapy for at least 3 days after culture 250 
was associated with a substantial protective effect on mortality among our large, 251 
national, real-world cohort with S. aureus bacteremia. These findings were robust in our 252 
primary analyses using propensity score matching, and in our sensitivity analyses using 253 
propensity score quintile adjustment and inverse probability of treatment weighting. In 254 
vitro research suggests statins may confer protective effects in S. aureus bacteremia 255 
since they i) inhibit S. aureus invasion of human endothelial cells (2, 11); ii) interfere 256 
with S. aureus biofilm formation (22); and iii) enhance clearance of S. aureus by 257 
phagocytes through the induction of DNA-based extracellular traps (12).  Consistent 258 
with our findings, several meta-analyses have identified protective effects with statins on 259 
all-cause mortality among patients with various types of infections. Pleiotropic effects 260 
with statins were evaluated among patients with sepsis, pneumonia, or bacteremia by 261 
pooling 20 published studies (13). The authors reported a 50% reduced mortality in 262 
statin users (pooled OR 0.49, 95% CI 0.37-0.61). The bacteremia-related mortality 263 
(evaluated in 4 studies out of 20) was also significantly lower in statin users (pooled OR 264 
0.33, 95% CI 0.09-0.75). Another meta-analysis found that outpatient use of statins was 265 
associated with a 29% decreased risk of all-cause mortality in patients with any infection 266 
(pooled OR across 41 studies 0.71, 95% CI 0.64-0.78) (14).   267 
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 268 
Among the included studies in both meta-analyses, exposure periods prior to 269 
hospitalization (pretreated) and after hospitalization (continuation, de novo) varied 270 
widely, and sensitivity analyses by statin exposure timing and duration were not 271 
conducted (13, 14). Indeed, some studies have included patients with such varied statin 272 
exposures, application of the study findings to clinical practice would not be possible. 273 
One observational study defined statin use as presence of a statin on the day of culture, 274 
regardless of previous or continued use (23). This statin exposure definition combined 275 
both prevalent (of unknown timing and duration) and incident statin users, as well as 276 
patients continuing and not continuing statin therapy. Not surprisingly, statin use in this 277 
study was not associated with reductions in 90-day mortality, ICU admission, or 278 
hospital/ICU discharge when adjusting for confounders, including indications for statin 279 
therapy, using propensity score methods (23).  280 
 281 
In our study, pretreated patients who continued on statin therapy experienced decreased 282 
rates of mortality while these protective effects were not observed in pretreated patients 283 
who did not continue statin therapy or in patients with de novo use. These results support 284 
statin continuation through the period of inflammation, as effects on the inflammatory 285 
response are no longer observed once the statin is discontinued (24). Similar results were 286 
observed in a multicenter randomized placebo-controlled trial of 250 patients with severe 287 
sepsis assigned to statin therapy (n=123) or placebo (n=127) (8). Randomization 288 
accounted for prior statin use, defined as at least 2 weeks of statin use prior to 289 
hospitalization (prevalent users) or no use in the 2 weeks before admission; those with 290 
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less than 2 weeks of statin use prior to admission were excluded. Pretreated statin users 291 
assigned to statin therapy had a lower 28-day mortality (5% vs 11%; p = 0.01) compared 292 
to placebo, although like our study, inpatient mortality was not significantly lower. Further, 293 
28-day mortality in de novo users was similar to the placebo group (16.3% vs 14.9%; 294 
p=0.78). It should be noted that duration of previous statin use was not assessed in the 295 
clinical trial and as such, variations in outcomes may have existed by duration. Although 296 
the study size was likely too small to detect any such differences (pretreated assigned to 297 
statins n=37, pretreated assigned to placebo n=40). 298 
 299 
We only know of one other study specifically examining the effects of statins on patient 300 
mortality in S. aureus bacteremia (25). A prospective cohort study, which included 160 301 
S. aureus bacteremia episodes from one hospital in Spain, found that the 33 statin 302 
users were less likely to die within 14 days than non-users (adjusted odds ratio [OR] 303 
0.08, 95% CI 0.01-0.66) but a significant difference between groups was not observed 304 
for 30-day (adjusted OR 0.35, 95% CI 0.10-1.23; p=0.10). Statin exposure was defined 305 
as prevalent statin use at bacteremia onset, and all users had at least one month of 306 
previous statin therapy. Another limitation of this Spanish study, besides prevalent statin 307 
use, was that 23/33 (70%) of the statin users had a vascular catheter as the source of 308 
bacteremia, compared to only 46/127 (36%) in non-users. Given that vascular catheters 309 
are a readily removable source of bacteremia with lower mortality rates than other 310 
sources, such a difference is difficult to ignore (26). In our study, catheter source was 311 
similar between statin exposure groups and non-users (Table 1).  312 
 313 
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Although most observational studies have confirmed the protective effects of statins on 314 
clinical outcomes in bacterial infections (25, 27-29), there is a concern surrounding this 315 
association due to the possibility of healthy user bias (30, 31). Patients taking 316 
preventive medications, such as statins, are more likely to have healthier behaviors 317 
resulting in favorable outcomes, including lower mortality rates, compared with sicker 318 
patients (32, 33). A multicenter inception cohort study conducted by Yende et al. 319 
supported this trend among statin users, providing evidence that statin use was 320 
significantly associated with good health behaviors, including health insurance, good 321 
functional status, and immunizations (34). Our approach to minimizing healthy user bias 322 
in our study was three-fold (35). First, we designed our study to only include incident 323 
statin users and to assess patients continuing statin therapy as one exposure group and 324 
those not continuing as a separate exposure group, both of which were compared to a 325 
common reference group of non-users. Second, we included proxies for healthy 326 
behaviors in our propensity score model, including use of preventative services (e.g. 327 
vaccination and health screenings) and conditions that impact health behaviors. Third, 328 
we implemented propensity score matching to identify non-users with similar 329 
distributions of important patient characteristics related to health. By excluding prevalent 330 
statin users, we believe our study minimized the potential for healthy user bias as this 331 
bias is observed in chronic medication use (31). 332 
 333 
There are limitations in our study. First, although we employed propensity score 334 
methods to address potential confounders of the association between use of statins and 335 
the clinical outcomes, we were unable to control for unmeasured confounding. These 336 
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methods allowed us to balance confounders of the exposure-outcome relationship that 337 
were included in the propensity score, however it could not control for unbalanced 338 
factors that were not measured in our study. Second, variations in point estimates were 339 
observed with propensity score matching, adjustment, and inverse probability of 340 
treatment weighting. Though propensity score matching produced the most 341 
conservative estimates, it also resulted in the greatest balance between groups. Third, 342 
we attempted to identify incident statin use in order to assess the effect of statins at the 343 
time of S. aureus infection. We defined incident use as initiation in the 30 days prior to 344 
culture, with no prior statin exposure in the previous year. As such, incident use did not 345 
necessarily mean throughout the patient’s lifetime. Therefore, our estimates may not 346 
completely rule out the influence of historical statin use (beyond the window that we 347 
defined in this study) on the outcomes. Fourth, our study results should be applied 348 
carefully in the general population since our study was conducted among Veterans, and 349 
approximately 98% were male. Fifth, as a retrospective study of existing data, the 350 
accuracy of operational definitions depends on the data source. Though we utilized one 351 
of the most comprehensive and accurate data sources for health outcomes research 352 
available in the United States, misclassification may still occur. For example, culture 353 
source is a free text field in the microbiology data, and therefore, without mention of a 354 
catheter in that field, we could not determine whether it was a catheter source. Lastly, 355 
we did not assess outcomes for specific statins or doses, which is an important area of 356 
inquiry as some data suggests added benefit of high potency or high dose statins (36, 357 
37). 358 
 359 
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Conclusions 360 
Our large, national, real-world cohort study showed that continuation of statins in recent 361 
initiators significantly lowered the risk of 30-day mortality in S. aureus bacteremia. By 362 
continuing statins in 10 patients, 1 death would be prevented in the 30 days after 363 
culture. New initiation of statins as adjunctive therapy to antibiotics still requires further 364 
investigation as a potential measure to optimize positive clinical outcomes, and should 365 
include clinical observational research and pragmatic trials to assure greater real-world 366 
application of the findings.367 
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Table 1. Demographic and hospitalization-related characteristics in statin users 
and non-users 
Characteristics 
Unexposed 
(n=16448) 
Pretreated 
without 
continuation  
(n=344) 
Pretreated 
with 
continutation 
(n=159) 
De novo 
(n=187) 
Age (years) 67.0 ± 12.5 69.7 ± 10.9* 71.7 ± 10.5* 
71.6 ± 
11.3* 
Body mass index  26.6 ± 7.1 28.3 ± 7.1* 27.3 ± 6.8 27.3 ± 6.5 
Male gender 
16068 
(97.7) 
341 (99.1) 157 (98.7) 183 (97.9) 
White race 
10202 
(62.0) 
250 (72.7)* 105 (66.0) 112 (59.9) 
Hispanic ethnicity 1013 (6.2) 18 (5.2) 7 (4.4) 9 (4.8) 
Year     
2002-2005 6605 (40.2) 121 (35.2) 54 (34.0) 48 (25.7)* 
2006-2009 5621 (34.2) 133 (38.7) 59 (37.1) 72 (38.5)* 
2010-2013 4222 (25.7) 90 (26.2) 46 (28.9) 67 (35.8)* 
Admission source     
Home 
14632 
(89.0) 
303 (88.1)* 145 (91.2)* 161 (86.1) 
Hospital 669 (4.1) 24 (7.0)* 10 (6.3)* 14 (7.5) 
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Nursing home 1147 (7.0) 17 (4.9)* 4 (2.5)* 12 (6.4) 
Intensive care at culture 3262 (19.8) 78 (22.7) 47 (29.6)* 49 (26.2)* 
Treating specialty     
General medicine 9807 (59.6) 185 (53.8) 82 (51.6)* 106 (56.7)* 
Intensive care 3468 (21.1) 85 (24.7) 50 (31.5)* 56 (29.9)* 
Surgery 1749 (10.6) 47 (13.7) 22 (13.8)* 17 (9.1)* 
Other 1424 (8.7) 27 (7.8) 5 (3.1)* 8 (4.3)* 
Region of facility     
Midwest 3096 (18.8) 58 (16.9) 30 (18.9)* 39 (20.9)* 
Northeast 2295 (13.9) 50 (14.5) 14 (8.8)* 32 (17.1)* 
South 7372 (44.8) 151 (43.9) 99 (62.3)* 94 (50.3)* 
West 3685 (22.4) 85 (24.7) 16 (10.1)* 22 (11.8)* 
Source of infection1)     
Catheter 349 (2.1) 10 (2.9) 3 (1.9) 2 (1.1) 
Endocarditis2) 579 (3.5) 8 (2.3) 2 (1.3) 13 (6.9) 
Respiratory culture site 1216 (7.4) 27 (7.8) 9 (5.7) 7 (3.7) 
Skin and soft tissue 
culture site 
2130 (12.9) 55 (16.0) 14 (8.8) 25 (13.4) 
Urine 2083 (12.7) 31 (9.0)* 7 (4.4)* 31 (16.6) 
S. aureus pathogen     
MRSA infection 8184 (49.8) 172 (50) 73 (45.9) 78 (41.7)* 
MSSA infection 8264 (50.2) 172 (50.0) 86 (54.1) 109 (58.3)* 
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Sepsis 
13676 
(83.2) 
269 (78.2)* 115 (72.3)* 156 (83.4) 
 
Data are mean ± standard deviation or number (%) of patients. 
MRSA=methicillin-resistant Staphylococcus aureus, MSSA=methicillin-susceptible 
Staphylococcus aureus  
1) Culture-confirmed source of infection ±24 hours from culture collection unless 
indicated otherwise. 
2) Source of infection identified from ICD-9-CM diagnosis codes ±24 hours from culture 
collection.  
* p<0.05 for pairwise comparison between statin exposure group and non-user group. 
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Table 2. Clinical characteristics and health service utilization in statin users and 
non-users 
Characteristics 
Unexposed 
(n=16448) 
Pretreated 
without 
continuation 
(n=344) 
Pretreated 
with 
continuation 
(n=159) 
De novo 
(n=187) 
Time to antibiotic treatment 
initiation from culture 
collection (days) 
0 (1-0) 0 (1-0) 0 (1-0) 0 (1-0) 
Length of antibiotic therapy 
(days) 
9 (15-5) 9 (14.5-6) 10 (14-6) 10 (15-6) 
Time to culture collection 
from admission (days) 
0 (5-0) 2 (9-0)* 4 (10-1)* 0 (0-0)* 
Surgery during current 
admission 
5808 (35.3) 123 (35.8) 65 (40.9) 62 (33.2) 
Comorbidity during current 
admission 
    
Charlson score  3.2 ± 2.7 3.4 ± 2.6 3.4 ± 2.6 3.3 ± 2.5 
Alcohol abuse 820 (5.0) 12 (3.5) 12 (7.6) 10 (5.4) 
Cancer 1798 (10.9) 34 (9.9) 13 (8.2) 7 (3.7)* 
Cardiac arrhythmia 2348 (14.3) 71 (20.6)* 32 (20.1)* 35 (18.7) 
Cerebrovascular disease 1465 (8.9) 49 (14.2)* 25 (15.7)* 38 (20.3)* 
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Chronic renal disease 1783 (10.8) 47 (13.7) 23 (14.5) 27 (14.4) 
Chronic respiratory 
disease 
815 (5.0) 15 (4.4) 12 (7.6) 6 (3.2) 
Congestive heart failure 2924 (17.8) 99 (28.8)* 57 (35.9)* 57 (30.5)* 
Coronary heart disease 1703 (10.4) 88 (25.6)* 55 (34.6)* 53 (28.3)* 
Diabetes 5607 (34.1) 170 (49.4)* 58 (36.5) 83 (44.4)* 
Hypertension 8175 (49.7) 210 (61.1)* 99 (62.3)* 111 (59.4)* 
Mild liver disease 1792 (10.9) 10 (2.9)* 8 (5.0)* 8 (4.3)* 
Myocardial infarction 860 (5.2) 52 (15.1)* 42 (26.4)* 45 (24.1)* 
Peripheral vascular 
disease 
414 (2.5) 19 (5.5)* 5 (3.1) 4 (2.1) 
Medication use during 
current admission 
    
Anti-hypertensive 
medication 
11590 
(70.5) 
306 (88.9)* 148 (93.1)* 163 (87.2)* 
Diuretic 7896 (48.0) 209 (60.8)* 87 (54.7) 95 (50.8) 
Diabetic medication (oral) 1971 (12.0) 68 (19.8)* 17 (10.7) 32 (17.1)* 
Insulin 8174 (49.7) 229 (66.6)* 81 (50.9) 100 (53.5) 
Corticosteroid 4283 (26.0) 99 (28.8) 27 (17.0)* 37 (19.8) 
H2RA/PPI 12656 
(76.9) 
283 (82.3)* 129 (81.1) 133 (71.1) 
NSAID 2820 (17.1) 46 (13.4) 18 (11.3) 29 (15.5) 
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Medical conditions in year 
prior to current admission1) 
    
     Low-density lipoprotein   
     testing 
8358 (50.8) 220 (64.0)* 106 (66.7)* 88 (47.1) 
Low-density lipoprotein 
(mg/dL) 
83 (62-107) 82 (60-116) 89 (68-121)* 87 (65-120) 
Previous alcohol abuse 632 (3.8) 9 (2.6) 5 (3.1) 2 (1.1)* 
Previous cancer 897 (5.4) 18 (5.2) 2 (1.3)* 7 (3.7) 
Previous cardiac 
arrhythmia 
1220 (7.4) 36 (10.5)* 13 (8.2) 12 (6.4) 
Previous chronic renal 
disease 
968 (5.9) 23 (6.7) 9 (5.7) 10 (5.4) 
Previous chronic 
respiratory disease 
471 (2.9) 9 (2.6) 1 (0.6) 3 (1.6) 
Previous coronary heart 
disease 
1219 (7.4) 64 (18.6)* 25 (15.7)* 19 (10.2) 
Previous hypertension 9313 (56.6) 236 (68.6)* 96 (60.4) 99 (52.9) 
Previous mild liver 
disease 
1030 (6.3) 11 (3.2)* 6 (3.8) 8 (4.3) 
Previous myocardial 
infarction 
654 (4.0) 47 (13.7)* 15 (9.4)* 15 (8.0)* 
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Previous skin or 
subcutaneous tissue 
infection 
892 (5.4) 24 (7.0) 6 (3.8) 17 (9.1)* 
History of medication use2)     
Anti-hypertensive 
medication 
10253 
(62.3) 
314 (91.3)* 143 (89.9)* 93 (49.7)* 
Diuretic 6836 (41.6) 210 (61.1)* 92 (57.9)* 49 (26.2)* 
Diabetic medication (oral) 2336 (14.2) 98 (28.5)* 21 (13.2) 28 (15.0) 
Insulin 5330 (32.4) 196 (57.0)* 77 (48.4)* 40 (21.4)* 
Corticosteroid 3880 (23.6) 92 (26.7) 31 (19.5) 24 (12.8)* 
H2RA/PPI 9455 (57.5) 262 (76.2)* 110 (69.2)* 59 (31.6)* 
NSAID 3312 (20.1) 78 (22.7) 23 (14.5) 19 (10.2)* 
     Influenza vaccination 2010 (12.2) 44 (12.8) 15 (9.4) 26 (13.9) 
Previous surgery1) 4956 (30.1) 115 (33.4) 32 (20.1)* 43 (23.0)* 
Previous hospitalization1) 9294 (56.5) 220 (64.0)* 78 (49.1) 75 (40.1)* 
Previous nursing home stay1) 1596 (9.7) 24 (7.0) 9 (5.7) 12 (6.4) 
 
Data are mean ± standard deviation, median (interquatile range q1-q3) or number (%) 
of patients. 
H2RA=histamine-2 receptor antagonist; PPI=proton pump inhibitor; NSAID= non-
steroidal anti-inflammatory drug. 
1) Present in the 1 year prior to the Staphylococcus aureus bacteremia hospitalization. 
2) Present in the 90 days prior to the Staphylococcus aureus bacteremia hospitalization. 
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3)Source of infection identified from ICD-9-CM diagnosis codes. 
* p<0.05 for pairwise comparison between statin exposure group and non-user group.  
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Table 3. Clinical outcomes in propensity matched statin users and non-users  
Outcomes 
No. of events/No. of patients 
HR (95% CI) 
 
 
 
  
Statin users Non-users    
30-day mortality          
Pretreated without 
continuation 63/331 70/331 0.92 (0.64 - 1.32) 
   
Pretreated with 
continuation  19/141 33/141 0.46 (0.25 – 0.84) 
   
De novo 27/177 27/177 1.04 (0.60 – 1.82)    
14-day mortality        
Pretreated without 
continuation  40/331 54/331 0.76 (0.50-1.16) 
   
Pretreated with 
continuation  9/141 20/141 0.35 (0.15-0.83) 
   
De novo 16/177 16/177 1.14 (0.56-2.34)    
Inpatient mortality       
Pretreated without 
continuation 53/331 60/331 0.70 (0.43 - 1.14) 
   
Pretreated with 
continuation 21/141 27/141 0.54 (0.22 – 1.35) 
   
De novo  21/177 19/177 1.00 (0.45 – 2.23)    
Discharge        
Pretreated without 
continuation 278/331 271/331 1.00 (0.79-1.27) 
   
Pretreated with 
continuation 120/141 114/141 1.10 (0.78-1.56) 
   
De novo  156/177 158/177 0.96 (0.71-1.31)    
ICU discharge        
Pretreated without 
continuation 61/72 52/68 0.63 (0.20-1.91) 
   
Pretreated with 
continuation 33/39 17/28 0.50 (0.05-5.51)    
De novo  33/42 32/39 0.20 (0.02-1.71)    
30-day readmission        
Pretreated without 
continuation 83/278 58/271 1.68 (1.12 - 2.52) 
   
Pretreated with 
continuation 27/120 34/114 0.62 (0.33 – 1.15) 
   
De novo  33/156 42/158 0.67 (0.40 – 1.12)    
30-day S. aureus re-
infection  
       
Pretreated without 
continuation 20/278 16/271 1.07 (0.52-2.22) 
   
Pretreated with 
continuation 5/120 7/114 0.67 (0.19-2.36) 
   
De novo 4/156 9/158 0.50 (0.15-1.66)    
          
Sooner 
outcomes in 
non-users 
Sooner 
outcomes in 
statin users 
0 1 2
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HR=hazard ratio; CI=confidence interval; ICU=intensive care unit; DC=discontinued. 
Propensity score matched within a 0.005 caliper range. The propensity score was 
derived from an unconditional logistic regression model and controlled for the variables 
listed in Supplemental Tables 2-4.  
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Figure 1. Study cohort identification. MRSA= methicillin-resistant Staphylococcus 
aureus; MSSA=methicillin-susceptible Staphylococcus aureus   
 
  
• No antibiotic treatment 
within 48 hours of culture 
(N=4,106) 
• No antibiotics active against 
MRSA/MSSA (N=4,882)
Statin users 
N=690 
• Pre-treated and 
not continued 
(N=344) 
• Pretreated and 
continued at 
least 3 days 
(N=159) 
• De novo use 
continued at 
least 3 days 
Non-users  
N=16,448 
Excluded 
Death or discharge within 2 days of 
antibiotic treatment initiation 
(N=1,812) 
Use of statins in the year prior to 
culture collection (N=10,931) or 
other statin use not evaluated in this 
study (N=520) 
Adult inpatients with positive S. aureus  
blood cultures, 2002-2013 
N=39,389 
Patients receiving appropriate antibiotics within 48 
hours of culture collection 
N=30,401 
No death or discharge within 2 days of antibiotic 
treatment initiation  
N=28,589 
Study cohort meeting inclusion and exclusion criteria  
N=17,138 
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Figure 2a. 14-day survival probability curve among propensity-matched statin 
users with continuation and non-users. 
Figure 2b. 30-day survival probability curve among propensity-matched statin 
users with continuation and non-users.  
 
 
S
ur
vi
va
l P
ro
ba
bi
lit
y
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Survival Time (Days)
0 1 2 3 4 5 6 7 8 9 10 11 12 13
Non-user Pretreated with continuation
S
ur
vi
va
l P
ro
ba
bi
lit
y
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Survival Time (Days)
0 10 20 30
Non-user Pretreated with continuation
